Akèy › Kansè fwa (Kasinòm epatoselilè) › Texas › Houston
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Houston, TX
31 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of ZW251 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Ap rekriteFaz 1/2
- Research Facility, Houston
National Liver Cancer Screening Trial
Ap rekriteFaz 4
- Baylor College of Medicine, Houston
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas Md Anderson Cancer Center, Houston
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Ap rekriteFaz 3
- Research Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Ap rekriteFaz 1/2
- Research Site, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
IDOV-Immune for Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- University of Texas MD Anderson Cancer Center, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Ap rekriteFaz 1
- Clinical Trial Site, Houston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Ap rekrite
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
Ap rekriteFaz 1
- The University of Texas M. D. Anderson Cancer Center, Houston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Ap rekrite
- M D Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA12-0, Houston
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Ap rekriteFaz 2
- Houston Methodist Hospital Cancer Center, Houston
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Ap rekriteFaz 1
- Oncology Consultants, Houston
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Ap rekriteFaz 2
- Baylor College of Medicine, Houston
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Ap rekriteFaz 2
- Houston Methodist Neal Cancer Center, Houston
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Ap rekriteFaz 4
- Houston Methodist Research Institute, Houston
Etid Kansè fwa (Kasinòm epatoselilè) nan lòt vil
- New York City, NY24 etid
- Dallas, TX19 etid
- Los Angeles, CA19 etid
- Boston, MA18 etid
- Cleveland, OH18 etid
- Philadelphia, PA16 etid
- Chicago, IL16 etid
- Pittsburgh, PA15 etid
- San Francisco, CA14 etid
- Orange, CA14 etid
- Jacksonville, FL14 etid
- San Antonio, TX13 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.